Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...3334353637383940414243...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Macular Atrophy (MA) in the Phase 2 Ladder Trial () -  Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_36;    
    P2
    Continuous delivery of ranibizumab through the PDS was not associated with an increased incidence or enlargement of MA compared with monthly ranibizumab injections. Future analyses of larger PDS datasets will be used to validate these observations.
  • ||||||||||  faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Effect of Dual Angiopoietin-2/VEGF-A Inhibition with Faricimab on Macular Anatomy in the STAIRWAY Ph2 Study of nAMD () -  Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_35;    
    P2
    Visual and anatomical improvements observed in the phase 2 STAIRWAY trial support preclinical evidence indicating that simultaneous Ang-2/VEGF-A neutralization results in sustained vascular stability, reduced leakage and anti-angiogenic effects, leading to sustained efficacy and durability of treatment effect beyond anti-VEGF monotherapy. Two large, global, phase 3 trials (TENAYA and LUCERNE) are currently underway to further investigate the efficacy and durability of faricimab compared to afibercept in nAMD.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. (Pubmed Central) -  Sep 13, 2020   
    In conclusion, treatment mainly with anti-vascular endothelial growth factor effectively improved visual acuity within 12 months (from 20/56 to 20/44 at 3 months and to 20/36 at 12 months). Aflibercept was superior to ranibizumab in achieving dry macula and reducing choroidal thickness at 3 months.
  • ||||||||||  JNJ-1887 / J&J
    Trial completion date:  AAVCAGsCD59 for the Treatment of Wet AMD (clinicaltrials.gov) -  Sep 7, 2020   
    P1,  N=25, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: Feb 2021 --> Jan 2022
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Anti-VEGF therapy in the treatment of neovascularization secondary to angioid streaks (a case report) (Pubmed Central) -  Sep 5, 2020   
    Currently, determination of the morphology and activity of CNV is done using multimodal macular imaging methods such as optical coherence tomography of the retina (OCT), optical coherence tomography angiography (OCT-A), fluorescin angiography (FA), indocyanine green angiography (ICGA) and autofluorescence. With the discovery of anti-VEGF therapy, it became possible to improve and stabilize functional results in this group of patients.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    New trial:  Intravitreal Ranibizumab in Recurrent ROP (clinicaltrials.gov) -  Sep 3, 2020   
    P,  N=115, Completed, 
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal, Real-World Evidence:  Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study. (Pubmed Central) -  Sep 1, 2020   
    One year results from the LUMINOUS real-world study showed a clinically meaningful VA improvement with ranibizumab in treatment-naïve patients with BRVO; numerically higher VA gains were achieved in patients who received more injections and those with poor baseline VA. No new safety signals were observed.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration. (Pubmed Central) -  Sep 1, 2020   
    OCT analysis showed decreased fluid from initial to final follow-up visit: 70.1-15.6% with sub-retinal fluid (SRF) and 47.3-18.8% with intra-retinal fluid (IRF) with no difference between the agents were used. This study demonstrates that most patients (74%) improve or maintain visual acuity long-term using a TAE model with a significant portion (45.1%) achieving 20/50 or better visual acuity with sustained treatment.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Clinical, Review, Journal:  The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review. (Pubmed Central) -  Aug 30, 2020   
    However, there was a greater polyp regression rate in the conbercept group at 12 months. This systematic review indicates that conbercept may achieve similar BCVA and CRT improvements as ranibizumab and aflibercept, with a superior rate of polyp regression at 12 months.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Virtual Reality Becomes a Reality for Ophthalmologic Surgical Clinical Trials. (Pubmed Central) -  Aug 26, 2020   
    P2, P3
    The Port Delivery System with ranibizumab (PDS) is an innovative, investigational drug delivery system designed for continuous delivery of ranibizumab into the vitreous to maintain therapeutic drug concentrations for extended durations...Besides the primary use of traditional training tools, physicians participating in Archway have an option to practice in computer-simulated environments provided by VR simulators before performing their first PDS implant insertion and refill-exchange procedures on patients. This Perspective article describes the unique advantages and technologic challenges that practice on VR simulators has to offer, and the experience of Archway physicians with VR technology as a first in any ophthalmic clinical trial.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    PK/PD data, Journal:  Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits. (Pubmed Central) -  Aug 22, 2020   
    This finding indicates a possibility to lengthen the injection interval to improve the efficacy of ranibizumab in human eyes. Our results highlight the potential for clinical application of a high-dose (10-fold) of anti-VEGF agents to prolong the intravitreal injection intervals, simultaneously improving the drug efficacy.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment open:  MERIT: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (clinicaltrials.gov) -  Aug 8, 2020   
    P3,  N=240, Recruiting, 
    In light of the natural evolution of nAMD, these data support the long-term efficacy of this treatment under real-world conditions of heterogeneity of patients and type of anti-VEGF used. Active, not recruiting --> Recruiting
  • ||||||||||  Journal:  The Microbiological Analysis of a Rhizobium radiobacter Outbreak After Intravitreal Injection (Pubmed Central) -  Aug 5, 2020   
    In our study, endophthalmitis that observed in ten patients caused by R.radiobacter bacteria after intravitreal ranibizumab injection in Ophthalmology Clinic were examined microbiologically...R.radiobacter isolates were found to be resistant to ampicillin, amoxicillin/clavulanate, trimethoprim/ sulfamethoxazole, cefotaxime and ceftazidime; susceptible to cefuroxime, cefepime, amikacin, gentamicin, imipenem, meropenem, ciprofloxacin, levofloxacin and piperacillin/tazobactam...Disinfection and antisepsis conditions, before and during the procedure, is important for the prevention of such infections. This study is the first epidemic outbreak report of endophthalmitis caused by the same strain of R.radiobacter and the second article in which R.radiobacter was reported as the cause of endophthalmitis after intravitreal injection.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Silicone oil droplets in repackaged anti-vascular endothelial growth factors for intravitreal injections: In search of the main source of contamination. (Pubmed Central) -  Aug 2, 2020   
    Two 16 mL vials of bevacizumab were repackaged at the compounding pharmacy to obtain four sets of product, each consisting of three 1.2 mL tubes of the drug repackaged in different ways...0.5 mL insulin syringes with staked-in needles used for supplying the product seem to be the main source of silicone oil contamination in repackaged anti-vascular endothelial growth factors. Silicone-free insulin syringes with staked-in needles would be strongly recommended for supplying anti-vascular endothelial growth factor intravitreal injections from compounding pharmacies.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  EVEREST study report 4: fluorescein angiography features predictive of polypoidal choroidal vasculopathy. (Pubmed Central) -  Aug 2, 2020   
    Silicone-free insulin syringes with staked-in needles would be strongly recommended for supplying anti-vascular endothelial growth factor intravitreal injections from compounding pharmacies. This study demonstrated that certain FA features can be predictive of PCV and may be considered as an indication for retina specialists to perform indocyanine green angiography as confirmatory test.